A new antifibrotic option for patients living with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures ...

AI and wireless sensing detect five common lung diseases touch-free, enabling early, personalised health monitoring.

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.8, a high estimate of $52.00 ...

Pune: The untimely death of a 25-year-old BHMS student in a Jalna two-wheeler accident on Dec 29, 2025, broke his family's ...

Global pulmonary function testing market growth is driven by rising prevalence of chronic respiratory diseases, increasing geriatric population, and growing adoption of diagnostic monitoring ...

A new development in wireless sensing technology that can reliably screen for five common pulmonary diseases could lead to ...

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...